ArticleInvestigational new drugs2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Toni K Choueiri et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this papertrialcites it